July 22, 2022 02:19 PM EDTUpdated 03:51 PM
Pharma

'We will con­tin­ue to fight': Con­tra­cep­tive com­pa­nies re­main hope­ful af­ter House pass­es bill

Nicole DeFeudis

Editor

A day af­ter the House passed a bill that would pro­tect Amer­i­cans’ right to con­tra­cep­tives, biotech ex­ecs say they will keep fight­ing for bet­ter ac­cess …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times